Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with IgA Nephropathy on Stable RAAS Blockade
Richard Lafayette, MD
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToKshama Mehta
Go Back To The Trial